This week's meeting, while likely dry and technical, "shows the public that this is how FDA is going about its decisions," one expert said.
Jon CohenSpeaking as a veteran of the FDA's vaccine advisory committee meetings--who, ahem, often struggles to stay awake--it's telling that @HelenBranswell and others are doing stories about the upcoming meeting before it has even happened.
Solidarity fails to find mortality benefits in four treatments—but the global trial itself wins praise
Jon CohenGilead's Remdesivir doesn't save lives. So says a large, multi-country study run by WHO's Solidarity trial network. An indepth look at the study by @kakape also notes that Gilead just cut a $1B deal with Europe for the drug.
How the world’s greatest public health organization was brought to its knees by a virus, the president and the capitulation of its own leaders, causing damage that could last much longer than the coronavirus.
How physician Deborah Birx’s unreasonable demands for hospital data created a “debacle” at CDC
Jon CohenA deep dive by @cpiller into the details of how the push by Deborah Birx to move hospital tracking to a private firm outraged CDC staffers, undermined the agency's already battered morale--and potentially will wreak havoc this winter.
President Trump’s recovery, while welcome by all, makes the public health communications challenge even more difficult, he said.
Jon CohenFauci tells @HelenBranswell that Trump's recovery "amplifies some of that misunderstanding that people have that it’s a benign disease and nobody has anything to worry about.” The infected, he stresses, also spread to the vulnerable. “It is a big deal.”
Rep. Mike Pence reflecting on the matter of biological origins on the floor of the United States House of Representatives.
Jon CohenThat sent prematurely. At last night's debate, VP Pence said, "We'll follow the science." Here's Rep. Pence in 2002 attacking teaching evolution without teaching intelligent design. He criticizes scientists for changing ideas as new data surface. c-span.org/video/?c463162…pic.twitter.com/cnw6BDJHfu
Minorities, the elderly and people with underlying health conditions are at highest risk of Covid-19, and are being prioritized for enrollment in large vaccine trials. Moderna's CEO said the company is slowing enrollment in its trial to ensure the...